🔍

MUKKA - Mukka Proteins

📊 NSE: MUKKA 🏢 Food - Processing - Indian 📅 Last Updated: 12/14/2025 10:06

📢 Recent Corporate Announcements

Mukka Proteins to Hold One-on-One Meeting with QRC Investment Advisors on March 12

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 05:54 PM

Mukka Proteins Limited has scheduled a virtual one-on-one meeting with QRC Investment Advisors LLP on March 12, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business performance based on publicly available data. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session. Investors should note that such meetings often indicate growing institutional interest in the company's specialized fish meal and fish oil business.

One-on-one virtual meeting scheduled with QRC Investment Advisors LLP.
The meeting is officially set for Thursday, March 12, 2026.
Company confirms compliance with SEBI Regulation 30 regarding disclosures.
No unpublished price sensitive information (UPSI) will be shared during the interaction.
Latest investor presentation remains the primary reference for the meeting's discussion.

💡 No immediate action is required as this is a routine corporate disclosure. Investors may review the company's latest investor presentation on their website to stay updated on business fundamentals.

Mukka Proteins to Meet ICICI Securities and Kotak MF on March 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 12:12 PM

Mukka Proteins Limited has announced a schedule for one-on-one virtual meetings with institutional investors on March 10, 2026. The company is set to interact with ICICI Securities and Kotak Mutual Fund to discuss business updates. These meetings are part of the company's routine investor relations activities following its regulatory requirements. Management has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

One-on-one virtual meetings scheduled for Tuesday, March 10, 2026.
Participation from major institutional entities including ICICI Securities and Kotak MF.
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company explicitly stated that no unpublished price sensitive information will be disclosed.

💡 This is a routine disclosure showing institutional interest; investors should monitor the company website for any updated investor presentations or meeting transcripts.

Mukka Proteins to Hold One-on-One Meeting with IFC on March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 05:01 PM

Mukka Proteins Limited has scheduled a virtual one-on-one meeting with the International Finance Corporation (IFC) on March 6, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates and strategy. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session. Engagement with a global body like the IFC often signals increasing institutional interest in the company's operations.

One-on-one virtual meeting scheduled with the International Finance Corporation (IFC) for March 6, 2026.
Compliance disclosure filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting.
The meeting schedule is subject to change based on the availability of the analyst or the company.

💡 This is a routine regulatory filing; no immediate action is required. Investors may review the latest investor presentation on the company's website to stay updated on the business outlook discussed with institutions.

Mukka Proteins Achieves MarinTrust Improver Programme Compliance for 3 Years

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 28 Feb 2026, 03:19 PM

Mukka Proteins Limited has received a confirmation letter from Global Trust Certification (NSF) for compliance with the MarinTrust Improver Programme for Responsible Supply of Marine Ingredients. This certification, valid for a period of 3 years, recognizes the company's use of Fishery Improvement Project (FIP) raw materials. The compliance reinforces the company's commitment to sustainability, traceability, and responsible sourcing in its marine ingredient supply chain. This development is expected to strengthen buyer confidence and enhance the company's competitive positioning in global markets.

Compliance confirmed by Global Trust Certification Ltd, Ireland, for the MarinTrust Improver Programme.
The certification is valid for a period of 3 years, ensuring long-term supply chain recognition.
Enables the company to source marine ingredients produced using Fishery Improvement Project (FIP) raw materials.
Provides assurance to global buyers regarding traceability and responsible sourcing practices.

💡 Investors should view this as a positive ESG development that improves the company's ability to cater to international markets with strict sustainability standards. Monitor if this certification leads to higher-margin export orders or new global partnerships.

Mukka Proteins Schedules One-on-One Meeting with Bandhan MF on Feb 28

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 12:36 PM

Mukka Proteins Limited has announced a virtual one-on-one meeting with Bandhan Mutual Fund scheduled for February 28, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates and performance. The company has confirmed that no unpublished price sensitive information (UPSI) will be shared during this session. Such meetings are standard practice for listed entities to maintain transparency with large fund houses.

One-on-one virtual meeting scheduled with Bandhan Mutual Fund for February 28, 2026.
Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
Company explicitly stated that no unpublished price sensitive information will be disclosed.
Latest investor presentation remains available on the company's official website for public review.

💡 No immediate action is required as this is a routine institutional interaction. Investors may monitor the company's website for any updated presentations or meeting transcripts.

Mukka Proteins Completes Acquisition of Ento Proteins; Becomes Wholly Owned Subsidiary

🟢 POSITIVE ⭐ 7/10

M&A 📅 24 Feb 2026, 11:40 AM

Mukka Proteins Limited has finalized the acquisition of 1,000 equity shares of Ento Proteins Private Limited (EPPL) for a total cash consideration of Rs. 32.30 Lakhs. Following this transaction, EPPL has become a wholly-owned subsidiary of the company effective February 23, 2026. EPPL is a manufacturer of insect meal and insect oil, reporting a turnover of Rs. 7.46 Crores and a PAT of Rs. 49.47 Lakhs for FY 2024-25. This acquisition aligns with Mukka Proteins' strategic plan to expand its presence in the alternate proteins market.

Acquired 1,000 equity shares for a total cash consideration of Rs. 32.30 Lakhs
Ento Proteins (EPPL) is now a 100% wholly-owned subsidiary of Mukka Proteins
EPPL reported a turnover of Rs. 7.46 Crores and PAT of Rs. 49.47 Lakhs for FY 2024-25
Target company specializes in the niche manufacturing of insect meal and insect oil
Strategic expansion into the high-growth alternate proteins business segment

💡 Investors should monitor the integration of this niche alternate protein business and its contribution to the consolidated bottom line. The acquisition is small but strategically sound for long-term diversification.

Mukka Proteins to Acquire Remaining 25.99% Stake in Ento Proteins for ₹32.3 Lakhs

🟢 POSITIVE ⭐ 6/10

M&A 📅 21 Feb 2026, 05:02 PM

Mukka Proteins Limited has entered into a Share Purchase Agreement (SPA) to acquire the remaining 25.99% equity stake in its subsidiary, Ento Proteins Private Limited. The company currently holds 74.01% of the investee company and will move to 100% ownership upon completion. The total cash consideration for the 1,000 equity shares is ₹32,30,000. This acquisition will result in Ento Proteins becoming a wholly-owned subsidiary and will terminate previous shareholder agreements.

Acquisition of remaining 25.99% stake in Ento Proteins Private Limited
Total cash consideration of INR 32,30,000 for 1,000 equity shares
Ownership stake increases from 74.01% to 100%, making it a wholly-owned subsidiary
Rescission and termination of the Shareholders’ Agreement dated September 7, 2021
Transaction involves acquisition from Holocene Ecosolutions Private Limited

💡 This is a routine consolidation of a subsidiary which simplifies the corporate structure. Investors should view this as a minor positive move to gain full control over the investee company's operations.

Mukka Proteins Q3 Revenue Jumps 115% YoY; Bags ₹475 Cr Order for Waste Management

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 04:54 PM

Mukka Proteins reported a robust Q3 FY26 with revenue surging 115% YoY to ₹653.5 crore, driven by strong export demand and operational scaling. The company secured a major ₹474.89 crore order for leachate treatment, marking a significant step in its waste-to-value diversification strategy. 9M FY26 revenue reached ₹1,068.9 crore, already exceeding the total FY25 revenue of ₹887 crore. Management has set an ambitious target of ₹2,500+ crore revenue by FY30, supported by capacity expansions and carbon credit initiatives.

Q3 FY26 revenue grew 115% YoY to ₹653.5 crore; 9M FY26 revenue reached ₹1,068.9 crore.
Secured a ₹474.89 crore order from BSWML for legacy leachate treatment over 4 years.
Carbon credit portfolio advanced with 300 TPD operations listed on Verra Registry and expansion to 1,000 TPD approved.
Board approved increasing stakes in Ento Proteins and Haris Marine Products to 100% ownership.
Export revenue share stands at 75.7% for 9M FY26, with a 25-30% domestic market share.

💡 Investors should monitor the execution of the large waste management contract and the progress of carbon credit issuance, which could significantly boost margins. The company's aggressive FY30 revenue target suggests strong management confidence in the integrated protein and sustainability platform.

Mukka Proteins Q3 Revenue Surges 115% to ₹653.5 Cr; Secures ₹475 Cr Waste Management Order

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 12:54 PM

Mukka Proteins reported a massive 115.57% YoY revenue growth in Q3 FY26, reaching ₹653.50 crore, driven by global fishmeal supply shortages and price recovery. While revenue more than doubled, EBITDA margins compressed significantly to 8.14% from 15.73% in the previous year's quarter. A major highlight is the strategic diversification into waste management with a new ₹474.89 crore order for legacy leachate treatment in Bengaluru. The company is also consolidating its subsidiaries and expanding its carbon credit-linked waste processing capacity to 1,000 TPD.

Q3 FY26 Revenue grew 115.57% YoY to ₹653.50 crore, while 9M FY26 revenue reached ₹1,068.85 crore.
Secured a large-scale order worth ₹474.89 crore for scientific treatment of legacy leachate from BSWML.
EBITDA stood at ₹53.21 crore with margins at 8.14%, reflecting a decline from 15.73% in the previous year.
Received incremental approval to expand BSF-driven wet-waste processing from 300 TPD to 1,000 TPD.
Consolidating ownership to 100% in Haris Marine Products and Ento Proteins to streamline operations.

💡 Investors should focus on the massive revenue scale-up and the significant diversification into high-margin waste management services which provides long-term visibility. However, the sharp contraction in EBITDA margins requires monitoring to ensure the company can pass on costs or optimize operations effectively.

Mukka Proteins to Acquire Remaining 25.99% Stake in Ento Proteins for Rs 32.3 Lakhs

🟢 POSITIVE ⭐ 7/10

M&A 📅 12 Feb 2026, 06:00 PM

Mukka Proteins has approved the acquisition of an additional 1,000 equity shares in its subsidiary, Ento Proteins Private Limited (EPPL), for Rs 32.30 lakhs. This transaction will increase Mukka's stake from 74.01% to 100%, making EPPL a wholly-owned subsidiary. EPPL is a niche manufacturer of insect meal and insect oil, reporting a turnover of Rs 7.46 crore and a PAT of Rs 49.47 lakhs for FY 2024-25. The move is part of Mukka's strategic plan to expand its presence in the alternate proteins market.

Acquisition of 1,000 equity shares to increase shareholding from 74.01% to 100%
Total cash consideration for the additional stake is Rs 32.30 lakhs
EPPL turnover grew from Rs 4.72 crore in FY23 to Rs 7.46 crore in FY25
Target entity EPPL reported a profit after tax (PAT) of Rs 49.47 lakhs in FY 2024-25
The acquisition is expected to be completed by June 30, 2026

💡 Investors should note this strategic consolidation in the high-growth alternate protein segment, which could provide long-term synergy benefits. The acquisition is priced reasonably relative to EPPL's profitability and revenue growth.

Mukka Proteins Updates Insider Trading Code of Conduct for Regulatory Compliance

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 12 Feb 2026, 05:47 PM

Mukka Proteins has amended its Code of Conduct for Regulating, Monitoring, and Reporting of Trading by Insiders as of February 12, 2026. The update, mandated by SEBI (Prohibition of Insider Trading) Regulations, 2015, strengthens internal controls over Unpublished Price Sensitive Information (UPSI). The Chief Financial Officer has been designated as the Compliance Officer to oversee adherence and report violations. This administrative update ensures the company remains compliant with evolving market regulations and maintains transparency in executive dealings.

Board approval granted on February 12, 2026, for the amended Insider Trading Code following Audit Committee recommendations.
CFO Mr. Kalandan Mohammed Althaf officially designated as the Compliance Officer for monitoring insider trades.
The code applies to all 'Designated Persons,' including promoters, directors, and key managerial personnel who have access to UPSI.
Established strict protocols for the 'need to know' sharing of sensitive information for legitimate business purposes with third parties.
The amendment aligns the company's internal policies with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 No action is required as this is a standard regulatory filing. Investors should view this as a routine governance update that reinforces the company's commitment to market integrity.

Mukka Proteins Q3 Revenue Surges 115% YoY to ₹6,535 Mn; Consolidates Subsidiaries

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 05:17 PM

Mukka Proteins reported a robust 115% YoY increase in consolidated revenue for Q3 FY26, reaching ₹6,534.97 million. While revenue grew significantly, the profit attributable to shareholders saw a slight decline to ₹237.48 million compared to ₹262.61 million in the previous year's quarter, primarily due to higher minority interest shares. The company also announced the strategic acquisition of remaining stakes in Ento Proteins and Haris Marine Products, making them wholly-owned subsidiaries. These acquisitions aim to consolidate operations in the fish and insect protein segments.

Consolidated revenue from operations grew 115% YoY to ₹6,534.97 million in Q3 FY26.
Consolidated Net Profit (PAT) for the quarter stood at ₹272.53 million, a significant recovery from ₹68.84 million in Q2 FY26.
Board approved the acquisition of additional shares in Ento Proteins and Haris Marine Products to make them 100% subsidiaries.
Nine-month revenue (9M FY26) reached ₹10,688.52 million, already surpassing the full-year FY25 revenue of ₹10,064.16 million.
Finance costs increased to ₹145.61 million in Q3 FY26 compared to ₹109.07 million in the same quarter last year.

💡 Investors should focus on the massive top-line expansion and the strategic move to full ownership of subsidiaries, while monitoring if the bottom-line growth can catch up to revenue pace in future quarters.

Mukka Proteins Q3 Revenue Surges 115% to ₹6,535 Mn; Consolidates Two Subsidiaries

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 05:13 PM

Mukka Proteins reported a massive 115.5% YoY increase in consolidated revenue for Q3 FY26, reaching ₹6,534.97 million. Despite the top-line surge, net profit attributable to shareholders saw a slight decline to ₹237.48 million from ₹261.52 million in the year-ago quarter, primarily due to a sharp rise in material and finance costs. Strategically, the board approved the acquisition of remaining stakes in Ento Proteins and Haris Marine Products, making them wholly-owned subsidiaries. The nine-month revenue of ₹10,688.52 million has already surpassed the total revenue for the entire previous fiscal year.

Consolidated revenue from operations grew 115.5% YoY to ₹6,534.97 million in Q3 FY26.
Nine-month revenue reached ₹10,688.52 million, exceeding the full FY25 revenue of ₹10,064.16 million.
Board approved making Ento Proteins and Haris Marine Products 100% subsidiaries through additional share acquisitions.
Finance costs rose to ₹145.61 million in Q3 FY26 compared to ₹109.07 million in Q3 FY25.
Basic EPS for the quarter stood at ₹0.79, down from ₹0.88 in the corresponding quarter of the previous year.

💡 Investors should monitor the company's margin profile as the bottom line is not yet scaling in tandem with the exceptional revenue growth. The move to make subsidiaries wholly-owned is a positive step toward operational integration and simplified corporate structure.

Mukka Proteins Lists BSF Project on Verra Registry; Expands Capacity to 1,000 TPD

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 27 Jan 2026, 08:51 AM

Mukka Proteins has achieved a significant milestone by listing its 300 TPD Black Soldier Fly (BSF) wet-waste processing project on the Verra Registry, paving the way for carbon credit (VCU) issuance. Furthermore, the company has received approval to expand this project's capacity from 300 TPD to 1,000 TPD within Bengaluru's waste management framework. This expansion is structured as a grouped project, allowing for phased inclusion of additional modules and progressively higher carbon credit generation. The move strengthens the company's revenue diversification through sustainable, circular-economy solutions.

BSF-based 300 TPD wet-waste project formally listed on Verra Registry under Project ID 5893
Received incremental approval to expand processing capacity from 300 TPD up to 1,000 TPD
Project follows ACM0022 methodology for Verified Carbon Standard (VCS) registration
Mukka Proteins maintains a 25-30% market share in India's fishmeal and fish oil sector
Total installed capacity across fishmeal and related products stands at 2,64,390 MT per year

💡 Investors should monitor the progress of the 30-day public comment period and subsequent VCU issuance as a new high-margin revenue stream. The successful scaling to 1,000 TPD will be a key driver for long-term valuation in the ESG and waste-to-value segments.

Mukka Proteins Forms New LLP for Waste Management with Rs. 5 Lakh Initial Capital

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 22 Jan 2026, 05:57 PM

Mukka Proteins Limited has executed an LLP agreement with Msjathin Infra Private Limited and Mr. Hardik Gowda to incorporate MPL HRC Ecosolutions LLP. This new entity will focus on the treatment and disposal of legacy leachate, water treatment, and bio-waste management. The initial capital contribution for the LLP is set at Rs. 5,00,000. The company's Managing Director & CEO, Mr. Kalandan Mohamed Haris, has been nominated as the Designated Partner for this venture.

Execution of LLP agreement with Msjathin Infra Private Limited and Mr. Hardik Gowda on January 22, 2026.
Incorporation of a new entity named MPL HRC Ecosolutions LLP for environmental services.
Initial capital contribution for the venture is Rs. 5,00,000.
Business scope includes treatment of legacy leachate, water, and bio-waste management.
MD & CEO Mr. Kalandan Mohamed Haris appointed as the Designated Partner in the LLP.

💡 Investors should view this as a strategic diversification into waste management services. While the initial capital is small, the progress of this venture should be monitored for its potential to scale and contribute to the company's ESG profile.

View All MUKKA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue from operations decreased by 27.06% YoY to INR 1,006.42 Cr in FY25. On a standalone basis, revenue fell 30.10% to INR 886.74 Cr. This decline was primarily driven by a normalization of global fish meal prices and a sales slowdown, following a period of high growth where the company saw a 28% CAGR between FY19 and FY24.

Geographic Revenue Split

The company maintains a robust international footprint across Asia, Europe, and the Middle East. While specific regional percentages for FY25 are not disclosed, the company is ranked 311th in the FT1000 High Growth Companies Asia-Pacific 2025, indicating significant regional contribution. Exports represent a healthy proportion of the revenue mix, reducing single-location exposure.

Profitability Margins

Consolidated Profit After Tax (PAT) decreased by 35.27% to INR 48.10 Cr in FY25. Standalone Net Profit Margin declined from 4.95% to 4.70% due to decreased profits. However, Standalone Operating Profit Margin improved from 5.97% to 7.92% in FY25, reflecting better cost management despite lower volumes.

EBITDA Margin

The PBILDT margin stood at 9.45% in H1 FY25, an improvement from 8.26% in FY24 and 4.96% in FY20. This long-term margin expansion is attributed to economies of scale and a favorable product mix, though H1 FY25 saw a 46% YoY decline in operating income to INR 327.7 Cr due to price normalization.

Capital Expenditure

The company is planning a fundraise of INR 98.0 Cr through a preferential allotment of equity shares. These funds are specifically earmarked for acquisitions and expansion towards business and product diversification, including the acquisition of a 68% stake in United Gulf Fishery Products LLC.

Credit Rating & Borrowing

CARE Ratings assigned a 'CARE BBB+; Stable / CARE A2' rating to bank facilities totaling INR 360 Cr (enhanced from INR 100 Cr) in January 2025. Interest coverage ratio decreased from 3.96 to 2.53 times in FY25 due to increased interest costs associated with higher working capital borrowings.

⚙️ Operational Drivers

Raw Materials

Raw fish is the primary raw material, used to produce fish meal and fish oil. While the exact percentage of total cost is not specified, it is the dominant cost driver, and the company is exposed to price volatility and seasonal availability of fish.

Import Sources

Sourcing is concentrated along the western coastline of India to ensure timely availability. The company is also expanding its sourcing footprint to Oman through the acquisition of United Gulf Fishery Products LLC to diversify its raw material base.

Key Suppliers

Not specifically named in the documents, but the company maintains established relationships with a wide network of suppliers across multiple coastlines to secure raw fish in sufficient quantities.

Capacity Expansion

The company currently operates 10 manufacturing facilities, 3 blending facilities, and 5 storage facilities. Expansion is planned through the acquisition of a 68% stake in United Gulf Fishery Products LLC and a planned INR 98 Cr investment in product diversification.

Raw Material Costs

Raw material costs are subject to inherent seasonality and volatility. The company utilizes a diversified sourcing strategy and optimizes production processes to mitigate these costs, which are impacted by government fishing bans and environmental factors.

Manufacturing Efficiency

The company utilizes sophisticated blending processes and stringent quality systems. Efficiency is supported by a workforce of 314 employees as of March 31, 2025, who undergo regular training to maintain competitive edges in production.

Logistics & Distribution

Not disclosed as a specific percentage of revenue, but the company notes that its geographically diversified production facilities reduce exposure to single-location logistics risks.

📈 Strategic Growth

Expected Growth Rate

28%

Growth Strategy

Growth will be achieved through a 68% stake acquisition in United Gulf Fishery Products LLC in Oman, a planned INR 98 Cr fundraise for product diversification, and leveraging its status as a high-growth Asia-Pacific company to expand its international footprint in Europe and the Middle East.

Products & Services

Fish meal, fish oil, and fish soluble paste, which are used as essential ingredients in aquaculture feed, poultry feed, and livestock raising.

Brand Portfolio

Mukka Proteins Limited; the company also operates through various subsidiaries and associates under the Mukka Group umbrella.

New Products/Services

The company is expanding into 'product diversification' supported by a planned INR 98 Cr fundraise, though specific new product names are not yet detailed.

Market Expansion

Targeting the Middle East through the STA (Share Transfer Agreement) for United Gulf Fishery Products LLC in Oman, signed on December 10, 2025.

Market Share & Ranking

Ranked 311th in the FT1000 High Growth Companies Asia-Pacific 2025 edition.

Strategic Alliances

Entered a Share Transfer Agreement with Mr. Saif Salim Ahmed Al-Rawahi to acquire 68% of United Gulf Fishery Products LLC. It also uses contractual arrangements with third-party manufacturing units to increase its presence on the western coastline.

🌍 External Factors

Industry Trends

The industry is shifting toward sustainable sourcing and high-quality standards (QEHS). Mukka is positioning itself by obtaining environmental clearances and pollution control licenses to meet stringent international customer validations.

Competitive Landscape

Mukka is a dominant player in the Indian fish meal/oil industry, competing based on its multi-coastline manufacturing presence and ability to meet international quality standards.

Competitive Moat

The company's moat is built on 50+ years of promoter experience and a dominant market position in the fish meal industry. This 'vintage' provides established customer relationships and a specialized manufacturing network that is difficult for new entrants to replicate quickly.

Macro Economic Sensitivity

The company is sensitive to the global economic outlook, which projects a slowdown to 2.3% growth in 2025. This impacts global demand for aquaculture and livestock feed, indirectly affecting Mukka's sales volumes.

Consumer Behavior

Increased global focus on protein-rich diets and aquaculture sustainability is driving long-term demand for high-quality fish meal and oil.

Geopolitical Risks

Exposure to international trade regulations and country-specific export licenses. The acquisition in Oman introduces risks related to Foreign Exchange Management (Overseas Investment) Regulations.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Export Inspection Council, pollution control boards, and country-specific export licenses. Any adverse change in Government of India export incentive rates would significantly hamper the business profile.

Environmental Compliance

Manufacturing facilities are subject to audit for pollution control and environment clearances. The company emphasizes 'environmental stewardship' as part of its risk management framework.

Taxation Policy Impact

The company complies with the Companies Act, 2013 and Indian Accounting Standards (Ind AS). Specific tax rate percentages are not disclosed, but the company noted a decrease in PBT of 31.09% and PAT of 35.27% for FY25.

Legal Contingencies

The auditor's report for FY25 is unmodified, and there are no 'Key Audit Matters' reported. No specific pending court case values in INR were disclosed in the provided documents.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the volatility of raw fish prices and global fish meal demand, which led to a 27.06% revenue decline in FY25. Environmental factors like fishing bans also pose a risk to raw material security.

Geographic Concentration Risk

While production is diversified across the western coastline of India, the company is expanding to Oman to reduce geographic concentration risk in raw material sourcing.

Third Party Dependencies

The company relies on contractual arrangements with third-party manufacturing units to supplement its own 10 facilities, creating some dependency on external production standards.

Technology Obsolescence Risk

The company uses sophisticated blending processes and has maintained an audit trail in its accounting software, with no instances of tampering found by auditors, indicating low digital risk.

Credit & Counterparty Risk

Debtors' turnover ratio decreased from 10.09 to 5.95 times in FY25, indicating a slowdown in collections and potential increase in credit risk from dealers who are offered sizeable credit periods.